PathAI, a global provider of artificial intelligence-powered technology for pathology, has announced the closing of its US$165 million Series C financing. PathAI will deploy its new capital to accelerate product development while continuing to prioritize the improvement of patient outcomes with reliable AI-powered technology and meaningful collaboration with pharmaceutical and diagnostic partners.
Latham & Watkins LLP represented PathAI in the financing with an emerging companies deal team led by Boston partner Stephen Ranere, with associate Samantha Gross.
